

PID Q2 2020-21

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
49461	18/WM/0347	250624	A Phase 3 study of BMS-986165 in participants with plaque psoriasis	Number Agreed	2	2	Date Agreed	15/07/2019	1	14/10/2019	1	Recruitment Finished	Competative recruitment
49462	19/EM/0016	253279	Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA	Number Agreed	3	3	Date Agreed	19/12/2019	0	19/03/2020	0	Withdrawn By Sponsor	withdrawn early due to COVID 19pandemic
49463	18/EM/0281	251974	Tralokinumab in moderate-severe AD extension trial 1337	Number Agreed	9	9	Date Agreed	28/11/2018	9	01/02/2020	9	Recruitment Finished	new measures for dispensing IMP had to be put in place due to COVID 19 pandemic .
49464	19/NE/0115	255707	SMR-3612	Range Agreed	2	6	Date Agreed	28/10/2020	3	06/07/2020	3	Withdrawn By Sponsor	On the 24th March

													2020 Almirall decided to pause recruitment until further notice because of the COVID-19 pandemic. However, due to the uncertainty of timelines and logistics of sites being able to recruit again, unfortunately Almirall have made the difficult decision to close recruitment for this study and will not re-open for further recruitment.
49465	19/YH/0158	262107	TRANSITION	Range Agreed	1	2	Date Agreed	03/03/2020	0	14/07/2020	0	Withdrawn By Sponsor	On 20th of March, Almirall

